---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-082910"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2025-09-02T23:59:59+00:00"
generated_at: "2026-05-17T08:51:02.562447+00:00"
event_type: "other"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Relmada Therapeutics CMO-Urology buys 55,000 shares in open market on Aug 29, 2025

## Summary
- Raj S. Pruthi, MD, Chief Medical Officer-Urology, purchased 55,000 shares of RLMD common stock on August 29, 2025.
- The purchase was executed via open market transactions; no specific price disclosed in filing.
- Insider purchase may signal management confidence in the company's outlook.

## SEC filing metadata
- accession: 0001213900-25-082910
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2025-09-02T23:59:59+00:00
- event_type: other
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390025082910/0001213900-25-082910-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390025082910/ea0255475-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-082910
- JSON: https://secwatch.observer/filing/0001213900-25-082910.json
- Plain text: https://secwatch.observer/filing/0001213900-25-082910.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.